Tag Archives: Biogen

Major Hospitals Won’t Carry New Alzheimer’s Med

Reuters reports: The rollout of Biogen Inc’s Alzheimer’s drug is hitting new roadblocks as some large hospitals decide not to use it and many health insurers await coverage terms from Medicare, the U.S. health plan for people aged 65 and older, before setting their own policies. Cleveland Clinic, one of the country’s best-known health systems, and New York’s Mount Sinai …

Read More »

CEO Defends $56K Annual Cost Of Alzheimer’s Med

CNBC reports: Biogen CEO Michel Vounatsos told CNBC on Monday that the list price of $56,000 per year for the company’s FDA-approved Alzheimer’s disease drug aducanumab is “fair.” That being said, the Massachusetts-based biotech company has vowed to not increase the price of the medication, which is marketed under the name Aduhelm, for the next four years, Vounatsos said. The …

Read More »